Innovative Technology Launch Depixus recently unveiled MAGNA One, the world's first laboratory instrument capable of analyzing individual biomolecular interactions at scale, presenting a unique selling point for advanced research facilities seeking cutting-edge tools.
Strategic Industry Recognition Receiving the 2024 SLAS Ignite Award highlights Depixus’s emerging reputation as an innovative leader, making it an attractive partner for collaborators and investors interested in pioneering interactomics solutions.
Recent Collaborations Partnerships with Daiichi Sankyo demonstrate an immediate interest from major pharmaceutical players in leveraging Depixus's technology for RNA-targeted drug discovery, indicating strong sales potential within biotech and pharma sectors.
Funding and Market Position With $35 million in funding and a focus on disruptive biotech innovations, Depixus is positioned to scale its sales efforts toward research institutions and drug development companies seeking next-generation interactomics tools.
Growth Opportunities Depixus's strategic hires, including a new Chief Commercial Officer, and active product launches suggest a ramp-up in sales activities targeting research labs, biotech companies, and pharmaceutical innovators interested in real-time biomolecular analysis.
$100M$250M
$250M$500M
$100M$250M
$1B$10B
$1B$10B
$50M$100M
$500M$1B
$500M$1B
$1B$10B
$500M$1B
$1B$10B
$1B$10BDepixus uses 8 technology products and services including SOLIDWORKS, WordPress, CookieYes, and more. Explore Depixus's tech stack below.
| Depixus Email Formats | Percentage |
| First.Last@depixus.com | 49% |
| First.Middle@depixus.com | 1% |
| First@depixus.com | 1% |
| First.Last@depixus.com | 49% |
Biotechnology ResearchFrance51-200 Employees
Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies.
Company Overview
Media & News
Funding & FinancialsDepixus has raised a total of $35M of funding over 4 rounds. Their latest funding round was raised on Dec 15, 2021 in the amount of $35M.
Depixus's revenue is estimated to be in the range of $1M
Funding & FinancialsDepixus has raised a total of $35M of funding over 4 rounds. Their latest funding round was raised on Dec 15, 2021 in the amount of $35M.
Depixus's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com